ATE110744T1 - Fibroblast-wachstumsfaktor. - Google Patents

Fibroblast-wachstumsfaktor.

Info

Publication number
ATE110744T1
ATE110744T1 AT86904536T AT86904536T ATE110744T1 AT E110744 T1 ATE110744 T1 AT E110744T1 AT 86904536 T AT86904536 T AT 86904536T AT 86904536 T AT86904536 T AT 86904536T AT E110744 T1 ATE110744 T1 AT E110744T1
Authority
AT
Austria
Prior art keywords
bfgf
growth factor
fibroblast growth
amino acid
acid residue
Prior art date
Application number
AT86904536T
Other languages
English (en)
Inventor
Frederick Stephen Esch
Andrew Baird
Peter Bohlen
Denis Jersy Gospodarowicz
Nicholas Chai-Kwan Ling
Original Assignee
Salk Inst For Biological Studi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25003873&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE110744(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Salk Inst For Biological Studi filed Critical Salk Inst For Biological Studi
Application granted granted Critical
Publication of ATE110744T1 publication Critical patent/ATE110744T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/839—Nerves; brain

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT86904536T 1985-06-20 1986-06-18 Fibroblast-wachstumsfaktor. ATE110744T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/747,154 US4956455A (en) 1984-03-05 1985-06-20 Bovine fibroblast growth factor

Publications (1)

Publication Number Publication Date
ATE110744T1 true ATE110744T1 (de) 1994-09-15

Family

ID=25003873

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86904536T ATE110744T1 (de) 1985-06-20 1986-06-18 Fibroblast-wachstumsfaktor.

Country Status (7)

Country Link
US (1) US4956455A (de)
EP (2) EP0597827A1 (de)
JP (1) JPH0829097B2 (de)
AT (1) ATE110744T1 (de)
CA (1) CA1341638C (de)
DE (1) DE3650055T2 (de)
WO (1) WO1986007595A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235042A (en) * 1984-02-29 1993-08-10 The Children's Medical Center Corporation Endothelial cell growth factor
US5155214A (en) * 1984-03-05 1992-10-13 The Salk Institute For Biological Studies Basic fibroblast growth factor
US5604293A (en) * 1985-09-12 1997-02-18 Scios Inc. Recombinant human basic fibroblast growth factor
EP0593065B1 (de) * 1985-09-12 2002-08-21 Scios Inc. Rekombinante Fibroblasten-Wachstums-Faktoren
US5859208A (en) * 1988-07-06 1999-01-12 Fiddes; John C. Human basic fibroblast growth factor analog
US5439818A (en) * 1985-09-12 1995-08-08 Scios Nova Inc. DNA encoding human recombinant basic fibroblast growth factor
US5026839A (en) * 1985-12-17 1991-06-25 Synergen, Inc DNA encoding a basic fibroblast growth factor
US4994559A (en) * 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
US7223842B1 (en) 1986-08-11 2007-05-29 Massachusetts Eye And Ear Infirmary Detection of proteins whose absence is associated with a neoplasm
US5853988A (en) * 1986-08-11 1998-12-29 Massachusetts Eye And Ear Infirmary Diagnosis of retinoblastoma
US7384735B1 (en) 1986-08-11 2008-06-10 Massachusetts Eye And Ear Infirmary Retinoblastoma nucleic acids
FI884252A0 (fi) * 1987-01-16 1988-09-15 Amgen Inc Foerfarande foer framstaellning av en fibroblasttillvaext-faktor.
US5852177A (en) * 1987-02-24 1998-12-22 Takeda Chemical Industries, Ltd. Basic fibroblast growth factor (bFGF) muteins
JP2526965B2 (ja) * 1987-02-24 1996-08-21 武田薬品工業株式会社 ムテイン，ｄｎａおよびその用途
US5750659A (en) * 1987-06-16 1998-05-12 New York University Mammalian growth factor
US5459250A (en) * 1987-06-16 1995-10-17 New York University Truncated mammalian growth factor DNA sequence
DE3721081A1 (de) * 1987-06-26 1989-01-19 Progen Biotechnik Gmbh Dna-sequenz, die codiert fuer ein zellteilungsfoerderndes polypeptid, sowie ein plasmid, ein wirtsorganismus und ein verfahren zur gewinnung dieses polypeptids
JP2879148B2 (ja) * 1987-07-07 1999-04-05 サイオス インコーポレイテッド 組換え繊維芽細胞成長因子
WO1989004832A1 (en) * 1987-11-24 1989-06-01 Amgen Inc. Analogs of fibroblast growth factor
EP0339905A3 (de) * 1988-04-25 1991-05-08 Ethicon, Inc. Wachstumfaktoren und Retinoiden enthaltende Wundheilungzusammensetzungen
US5126323A (en) * 1989-11-16 1992-06-30 Genetics Institute, Inc. Homogeneous purified k-fgf and compositions containing the same
GB9017008D0 (en) * 1990-08-02 1990-09-19 Erba Carlo Spa Process for the enzymatic preparation of basic fibroblast growth factor
DE69119869T2 (de) * 1990-11-23 1996-12-12 American Cyanamid Co Chimeres Fibroblasten-Wachstumsfaktor
AU1193492A (en) * 1991-01-03 1992-08-17 Salk Institute For Biological Studies, The Mitotoxin for treatment of vascular injury
US5206023A (en) * 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5492894A (en) * 1991-03-21 1996-02-20 The Procter & Gamble Company Compositions for treating wrinkles comprising a peptide
US5270300A (en) * 1991-09-06 1993-12-14 Robert Francis Shaw Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone
DE4132005A1 (de) * 1991-09-26 1993-04-01 Merck Patent Gmbh Kombination enthaltend wachstumsfaktoren und polyelektrolyte
AU659723B2 (en) * 1992-02-14 1995-05-25 Kaken Pharmaceutical Co., Ltd. Remedy for airway diseases
GB9203533D0 (en) * 1992-02-19 1992-04-08 Erba Carlo Spa Use of the conjugate between a fibroblast growth factor and a saporin in treating ocular pathologies
US5348941A (en) * 1992-04-01 1994-09-20 Merck & Co., Inc. Stabilizers for fibroblast growth factors
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US5795737A (en) * 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
KR100374310B1 (ko) * 1995-02-14 2003-05-22 주식회사 엘지생명과학 변형된인간염기성섬유아세포성장인자및이의생산방법
KR19990008319A (ko) * 1995-06-05 1999-01-25 벤슨로버트에이치 섬유아세포 성장 인자 15
US5773252A (en) * 1995-06-05 1998-06-30 Human Genome Sciences, Inc. Fibroblast growth factor 15
US6274712B1 (en) 1997-12-23 2001-08-14 3-Dimensional Pharmaceuticals, Inc. Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137
AU755943B2 (en) * 1998-08-13 2003-01-02 University Of Southern California Methods to increase blood flow to ischemic tissue
EP2123292B1 (de) 1998-09-03 2016-05-04 Novartis Vaccines and Diagnostics, Inc. FGF-2 angiogenische wirksame Einheitdosis und Verfahren zu ihrer Verwendung
US20030166550A1 (en) * 1999-08-27 2003-09-04 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US8618052B2 (en) 1998-10-13 2013-12-31 Novartis Vaccines And Diagnostics, Inc. Method of treating coronary artery disease by administering FGF-5
JP2002527401A (ja) * 1998-10-13 2002-08-27 カイロン コーポレイション Ｆｇｆの脈管形成的に有効な単位用量および投与方法
US6440934B1 (en) 1998-10-13 2002-08-27 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US20020072489A1 (en) * 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
JP5704780B2 (ja) * 1999-08-13 2015-04-22 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 脈管形成因子の用量および心筋血流を改善するための投与方法
EP1366148A2 (de) * 2001-01-24 2003-12-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES Differenzierung von stammzellen zu endokrinen pankreaszellen
US20030211605A1 (en) * 2001-05-01 2003-11-13 Lee Sang-Hun Derivation of midbrain dopaminergic neurons from embryonic stem cells
HUE025872T2 (en) 2002-06-18 2016-05-30 Eisai R&D Man Co Ltd Primary, cultured adipocytes for gene therapy
AU2004313245B2 (en) 2003-12-30 2011-04-14 Durect Corporation Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents, preferably a GNRH
WO2009026106A1 (en) 2007-08-16 2009-02-26 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Methods for promoting stem cell proliferation and survival
EP2310039B1 (de) * 2008-05-02 2014-07-16 University Of Western Ontario Fgf-9 und seine anwendung in verbindung mit blutgefässen
EP2951290B1 (de) 2013-02-01 2017-11-29 The United States of America, as represented by The Secretary, Department of Health and Human Services Verfahren zur erzeugung von zellen im retinalen pigmentepithel aus induzierten pluripotenten stammzellen
CA3051442A1 (en) 2017-02-14 2018-08-23 Alejandro Soto-Gutierrez Methods of engineering human induced pluripotent stem cells to produce liver tissue
SG11202104401RA (en) 2018-11-19 2021-05-28 The United States Of America As Represented By The Secretary Biodegradable tissue replacement implant and its use
CA3220602A1 (en) 2021-05-28 2022-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods to generate macular, central and peripheral retinal pigment epithelial cells
EP4346928B1 (de) 2021-05-28 2026-01-14 The United States of America, as represented by The Secretary, Department of Health and Human Services Biologisch abbaubares gewebegerüst mit sekundärmatrix zum hosten schwach adhärenter zellen
WO2024192329A1 (en) 2023-03-16 2024-09-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for producing stable human chondroctyes and their use for promoting cartillage growth and repair

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0593065B1 (de) * 1985-09-12 2002-08-21 Scios Inc. Rekombinante Fibroblasten-Wachstums-Faktoren
EP0241830A3 (en) * 1986-04-08 1990-01-10 The General Hospital Corporation Hepatoma-derived growth factor
DE4213967A1 (de) * 1992-04-29 1993-11-04 Basf Ag Waessrige polymerisatdispersion

Also Published As

Publication number Publication date
JPS63500036A (ja) 1988-01-07
CA1341638C (en) 2014-06-17
US4956455A (en) 1990-09-11
EP0228449A4 (de) 1989-04-24
WO1986007595A1 (en) 1986-12-31
JPH0829097B2 (ja) 1996-03-27
DE3650055T2 (de) 1994-12-15
EP0597827A1 (de) 1994-05-18
EP0228449B1 (de) 1994-08-31
DE3650055D1 (de) 1994-10-06
EP0228449A1 (de) 1987-07-15

Similar Documents

Publication Publication Date Title
DE3650055D1 (de) Fibroblast-wachstumsfaktor.
YU47735B (sh) Postupak za sintezu biološki aktivnih polipeptida limfotoksina
ATE71408T1 (de) Herstellungsverfahren fuer erythropoietin.
YU53290A (sh) Postupak za dobijanje novih jedinjenja insulina
BG101408A (bg) Аналози на кератиноцитния растежен фактор
GR850474B (de)
ES8704974A1 (es) Procedimiento para la obtencion de derivados de oligopeptido, de efecto tensioactivo compatible con la piel
NO895028D0 (no) Ny chimerisk transformerende vekstfaktor-beta.
DE3479734D1 (en) Novel, physiologically active polypeptides and production method thereof
NZ334568A (en) Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
IL88963A0 (en) Synthetic peptides and mixtures thereof for detecting hiv antibodies
AU6707686A (en) Prostate-derived growth factor
NO175872C (no) Plasmidvektor, fremgangsmåte for fremstilling av peptider og myelomcelle
IE810114L (en) N-benzyloxycarbonyl-l-aspartic acid
EP0249412A3 (en) C-terminal alpha-amidating enzyme and process for production and use thereof
ATE78872T1 (de) Herstellung von polypeptiden.
JPS6420086A (en) Polypeptide and production thereof
GR3007491T3 (de)
EP0687685A4 (de) Physiologisch-aktive peptide
ATE81675T1 (de) Produktion eines proteins.
DK157902C (da) Hoejkoncentrerede, vandige aminoxidpraeparater og fremgangsmaade til fremstilling heraf
TW243453B (en) Cloning and characterization of a cardiac adenylyl cyclase
ES8603380A1 (es) Un procedimiento para producir cristales de sal equimolar delirina y acido 2-hidroxi-4-metiltiobutirico
ATE52258T1 (de) Verfahren zur herstellung von 2-beta-dribofuranosylselenazol-4-carboxamid.
ZA869400B (en) A process for the preparation of 7alpha-acetylthiosteroids

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time